Search
Nurix Therapeutics Inc
NRIXAdd to Watchlist
18.675USD
+1.125+6.41%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
1.93BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Nurix Therapeutics Inc is 8.50, ranking 109 out of 389 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 41.00 and a low of 15.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
31.733
Target Price
+80.82%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Nurix Therapeutics Inc
NRIX
16
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Nurix Therapeutics Inc's expected revenue for the next quarter?
Nurix Therapeutics Inc's expected revenue is 16.17M.
What is Nurix Therapeutics Inc's price target?
Analysts forecast that Nurix Therapeutics Inc's price target is USD 28.00, with the highest forecast at USD 41.00 and the lowest forecast at USD 15.00.
How have Nurix Therapeutics IncNRIX's recent earnings per share performed?
The market expectation was USD -0.79, while Nurix Therapeutics IncNRIX's earnings per share (EPS) for the previous quarter was USD -0.82. EPS for the next quarter is expected at USD -0.72.
What is the analyst rating for Nurix Therapeutics Inc?
Based on the ratings of Nurix Therapeutics Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
